Boehringer Ingelheim Pharma Gmbh & Co Kg

Boehringer Ingelheim International Gmbh

Ralf R H Lotz

Frank Himmelsbach

Matthias Eckhardt

Elke Langkopf

Michael Mark

Gerald Juergen Roth

Roland Maier

Thorsten Lehmann-Lintz

Dirk Stenkamp

Stephan Georg Mueller

Mohammad Tadayyon

Klaus Rudolf

Leo Thomas

Philipp Lustenberger

Marcus Schindler

Martin Lenter

Armin Heckel

Joerg Kley

Marco Santagostino

Kirsten Arndt

Frank Hilberg

Ulrike Tontsch-Grunt

Jacobus C A Van Meel

Kristen Arndt

Philip Lustenberger

The present invention relates to substituted xanthines of general formula wherein Rto Rare as defined herein, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions

The present invention relates to alkyne compounds of general formula I wherein the groups and residues A, B, W, X, Y, Z, Rand Rhave the meanings given in claim. The invention further relates to pharmaceutical compositions containing at least one alkyne according to the invention. In view of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.

Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds

Compounds of formula I wherein the groups and residues A, B, b, X, Y, Z, R, R, R, Rand Rhave the meanings given in claim. The invention further relates to pharmaceutical compositions containing at least one amide according to the invention. As a result of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia, and diabetes.

&#x3b2;-ketoamide compounds with MCH antagonistic activity

Compounds of formula (I) wherein A, B, b, W, X, Y, Z, R, R, and Rhave the meanings given in claim, pharmaceutical compositions these compounds, and methods of preventing or treating metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia, and diabetes using these compounds.

Amide compounds with MCH antagonistic activity and medicaments comprising these compounds

The invention relates to new purine derivatives of general formula wherein Rto Rare defined as in the claims, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV), the preparation thereof, the use thereof for the prevention or treatment of diseases or conditions associated with an increased DPP-IV activity or capable of being prevented or alleviated by reducing the DPP-IV activity, particularly type I or type II diabetes mellitus, the pharmaceutical compositions containing a compound of general formula (I) or a physiologically acceptable salt thereof as well as processes for the preparation thereof.

Purine derivatives, the preparation thereof and their use as pharmaceutical compositions

The present invention relates to new substituted xanthines of general formula wherein R, Rand X are defined as in the claims, the tautomers, the enantiomers, the diastereomers, the mixtures thereof and the salts thereof, which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

3-methyl-7-butinyl-xanthines, the preparation thereof and their use as pharmaceutical compositions

Compounds of formula (I) wherein Ris a phenylcarbonylmethyl group wherein the phenyl moiety is substituted, and Rto Rare defined as in the claims, or the prodrugs or salts thereof, particularly the physiologically acceptable salts thereof, pharmaceutical compositions containing these compounds, and methods of treating type I and type II diabetes mellitus, arthritis, obesity, allograft transplantation and calcitonin-induced osteoporosis using these compounds.

Xanthine derivatives, their preparation and their use in pharmaceutical compositions

Disclosed are substituted xanthines of general formula wherein Rto Rare defined hereinbelow, the tautomers, the stereoisomers, the mixtures thereof, the prodrugs thereof and the salts thereof, which have valuable pharmacological properties, particularly an inhibitory effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions

The present invention relates to substituted xanthines of general formula wherein Rto Rare defined as in claimsto, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

The present invention relates to heterocyclically substituted indolinones of general formula wherein

Growing community of inventors

Schemmerhofen, Germany

Ralf R H Lotz